AIA-PACK Series

Tumor Markers

Meet the Challenges of Oncology Testing

Cancer incidence and mortality rates are rapidly growing worldwide. In 2018, the World Health Organization estimated that 9.6 million people worldwide would die from cancer - nearly 1 in 6 global deaths - leading to a significant economic burden. Between 30-50% of cancer deaths are preventable. Early diagnosis, screening and monitoring increase the likelihood of survival and lower morbidity rates.

Tosoh is committed to delivering the highest standard of quality, precision and accuracy in clinical diagnostics to aid in the fight against cancer. Our extensive tumor marker menu offered in a unique dry reagent test cup technology combined with our automated immunoanalyzers provide a comprehensive solution for oncology testing.

TUMOR MARKERS AVAILABLE

Total PSA	**27.29**	**CA 125**	**CA 19-9**	**AFP**	**CEA**

TOSOH BIOSCIENCE
www.tosohbioscience.us

TOSOH

Universal Reagent

Tosoh's AIA-PACK test cup format works with every Tosoh automated immunoassay system allowing for a seamless transition from one system to the other, ensuring consistent results in an efficient and economical process.

Save Time and Money

Tosoh's AIA-PACK test cups are single, unitized cups that use a dry reagent format that ensures calibration stability of up to 90 days.

No Contamination, More Traceability

Because there is no transfer of reagents the risk of contamination is eliminated. The unique bichromatic fluorescence kinetic measurement ensures a high analytical and functional sensitivity for all assays. AIA-PACK test cups and trays are labelled with the assay code and lot number for automated scheduling and inventory.

Features and Benefits

Tumor Marker	Disease	Indication	Assay Principle	Distinguishing Feature	Benefit
Prostate Specific Antigen (PSA)	**Prostate**	Screening, diagnosis and monitoring of prostate cancer	Hybritech® Equimolar Response Total PSA sandwich immunoassay	Equimolar assays that shows better diagnostic sensitivity and specificity compared to skewed assays[1]	■ Accurate assay with better discrimination between benign prostatic hyperplasia and prostate cancer[2] ■ Avoid unnecessary biopsies[3]
Cancer Antigen 27.29	**Breast**	Clinical management of breast cancer	Sandwich assay with unique capture and tracer antibodies	Assay targets both epitopes for CA27.29 (B27.29) and CA15-3 (DF3)	Monitoring of breast cancer recurrence, staging and response to therapy with single assay[4]

Choose Wisely. Choose Tosoh.

- Accurate & precise
- Specific & sensitive
- Correlation with gold standard methods
- No Biotin Interference — Biotin-free immunoassays
- Extensive test menu
- Up to 90 day calibration stability
- 10 min incubation times
- Automated workflows

Available for Labs and Workloads of All Sizes

AIA-360

AIA-900
Benchtop

AIA-900
with 9 Tray Sorter
Also available with 19 tray sorter option and as Loader model



AIA-2000

Tosoh products are for Prescription use only as In-Vitro Diagnostics

Tosoh Bioscience, Inc.
6000 Shoreline Court, Suite 101
South San Francisco, CA 94080
Tel: (800) 248-6764
Fax: (650) 615-0415
www.tosohbioscience.us

References

1. Prestigiacomo, et al. A Comparison of 4 Ultrasensitive Prostate Specific Antigen Assays for Early Detection of Residual Cancer after Radical Prostatectomy. The Journal of Urology 1994; 152: 1515-1519.
2. Andrew W. Roddam, et al. Assessing the Clinical Impact of Prostate-Specific Antigen Assay Variability and Nonequimolarity: A Simulation Study Based on the Population of the United Kingdom Clinical Chemistry. Vol. 50, Issue 6 June, 2004
3. Onur R, et al. Increased discrimination between benign prostatic hyperplasia and prostate cancer with equimolar total prostate specific antigen measurement. World J Urol 2003;21:43-47.
4. Klee, G., et al. MUC1 Gene-Derived Glycoprotein Assays for Monitoring Breast Cancer (CA15-3. CA 27.29, BR). Arch Pathol Lab Med -Vol 128, October 2004.

Part # AIA-TUM-SS01 Rev. 1/2019